Your prescription drugs shouldn’t cost more than your mortgage. Inside the broken math that got us here.
We will never make medicine affordable if how to tie a drug’s price to its value is solely determined by the companies creating the drugs.
The issue of unaffordable prescription drugs is a pressing concern for many individuals, and the article highlights a crucial aspect of the problem: the broken math that determines drug prices. The fact that a life-saving medication can cost more than a mortgage is unsustainable and has significant implications for public health and financial stability.
The pharmaceutical industry's practice of setting prices based on their own valuation of a drug's worth is a flawed approach. It creates a power imbalance, where companies have too much control over the pricing of essential medications. This approach also ignores the broader societal value of a drug, such as its impact on productivity, healthcare costs, and overall well-being. As a result, patients and healthcare systems bear the brunt of inflated prices.
To watch next: The industry's response to growing criticism and potential regulatory changes. Will there be a shift towards value-based pricing models, where drug prices are tied to their actual value to patients and society? Policymakers, patient advocacy groups, and pharmaceutical companies will be closely monitoring developments in this area. Specifically, look for updates on proposed legislation, such as efforts to allow Medicare to negotiate drug prices or the introduction of importation policies to increase competition.
Originally reported by marketwatch.com. OptionNews adds analysis for finance & markets readers.